Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma


Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Abhinav Deol, MD, physician, Karmanos Cancer Institute, associate professor, Clinical Hematology and Oncology, Wayne State University, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

When a patient with multiple myeloma is a candidate for CAR T-cell therapy, they must be referred to a cancer center that is capable of administering the treatment, which must be done at the appropriate time frame, Deol begins. Currently, there are 2 FDA-approved CAR T-cell therapies for patients with relapsed/refractory multiple myeloma: idecabtagene vicleucel (ide-cel; Abecma) was approved in March 2021, and ciltacabtagene autoleucel (cilta-cel; Carvykti) was approved in February 2022. Both treatments are indicated for patients who have progressed on 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Waiting until patients reach this point of their treatment journey before they are referred for CAR T-cell therapy is important to keep in mind, Deol adds.

Additionally, for patients who are appropriate candidates for CAR T-cell therapy, there are limitations regarding timelines for treatment, Deol notes. These limitations are due to the number of manufacturing slots available, and the time from referral to manufacturing of the CAR T product and treatment may take a few months, Deol expands. If there is a significant period of time between referral and treatment, a cohesive plan is needed to treat and manage patient during the interim to keep their disease is under control prior to CAR T-cell therapy, Deol says.

Finally, when patients are able to receive CAR T-cell therapy, there will be a period of time where they must be in a close proximity to the cancer center where they are receiving treatment, Deol says. Fortunately, many patients receiving CAR T-cell therapy may qualify for assistance programs to help them stay close to the cancer center with their caregiver so their disease can be appropriately managed.

Although CAR T-cell therapy is a great treatment option for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy, but there are still limitations to getting it to patients in a timely manner, Deol concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD